InnoCare Pharma entered into a strategic research collaboration and license agreement with Eli Lilly and Company to develop new medicines.

Under the terms of the deal, InnoCare is set to receive up to $100 million in upfront and near-term payments, plus up to approximately $3.25 billion in development and commercial milestone payments, bringing the agreement's total potential value to roughly $3.35 billion.¹

As part of the deal, InnoCare will also be eligible to receive single-digit tiered royalties based on annual net product sales for any products that reach the market.¹ The partnership adds InnoCare to a growing list of companies Eli Lilly has brought into its pipeline this year through licensing and acquisition deals.

What will the collaboration cover?

InnoCare is expected to leverage its proprietary drug discovery platform and research experience to discover and advance compounds against up to five targets, addressing what the company describes as critical unmet medical needs.¹

The companies have not disclosed which indications they plan to pursue.

"We are excited to leverage our R&D platform to collaborate with a global pharmaceutical leader like Lilly," said Dr. Jasmine Cui, co-founder, chairwoman and chief executive officer of InnoCare. "We are dedicated to expanding our partnership and innovation footprint."

Why does this deal matter for Lilly's dealmaking pace?

The InnoCare agreement is the latest in a string of business development moves for Eli Lilly, which has been among the most active dealmakers in pharma this year.² It follows an acquisition of Merida Biosciences that could reach up to $2.875 billion in value, bringing Eli Lilly the biotech's early-stage precision therapy candidate MER511 for thyroid eye disease and Graves' disease. In July, Eli Lilly paid $2.8 billion upfront, plus up to $1 billion in contingent value rights, to acquire AtaiBeckley, marking its entry into the psychedelics space.

Eli Lilly has also completed some of the largest takeovers in the sector this year, including the April acquisition of Kelonia Therapeutics, which could reach up to $7 billion in value, and the March purchase of Centessa Pharmaceuticals for up to $7.8 billion. Over the past decade, Lilly has acquired more biotechs than any of the other top 12 pharmaceutical companies by revenue, with 10 of those acquisitions coming this year alone.²

Pharmaceutical Executive spoke with K2 Therapeutics’ CEO Dr. Ying Huang about the growing shift towards globally sourced innovation and the increased focus on foreign partnerships, where he noted that, "Drug discovery is a lengthy and capital-intensive process. On average, it takes eight to ten years and between one and two billion dollars in total investment to bring a drug from discovery in the lab to FDA approval."

What happens next?

The financial structure of the InnoCare-Lilly agreement reflects the early, discovery-stage nature of the collaboration, with value weighted toward success on targets that have not yet been disclosed.

As Lilly continues a dealmaking pace that has already produced billions of dollars in acquisitions and partnerships this year, the InnoCare collaboration adds a research-stage bet to a portfolio otherwise dominated by later-stage and commercial-ready assets, leaving open which five targets the partners will ultimately pursue and how quickly compounds might advance toward the clinic.^1,2

Sources

1. InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines InnoCare September 24, 2026, https://www.globenewswire.com/news-release/2026/09/24/3367940/0/en/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines.html
2. Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare BioSpace September 24, 2026, https://www.biospace.com/deals/lilly-sets-aside-up-to-3-25b-to-tackle-critical-unmet-need-targets-with-innocare